usion medications.
Intravenously administer 1 L of isotonic solution (e.g. 5% Dextrose Injection, USP and 0.45% or 0.9% Sodium Chloride Injection, USP) over 2 to 4 hours after each LUMOXITIinfusion. Administer 0.5 L to patients under 50 kg.
Consider oral antihistamines and acetaminophen for up to 24 hours following LUMOXITIinfusions.
Consider oral corticosteroid (e.g. 4 mg dexamethasone) to manage nausea andvomiting.
Maintain adequate oral fluid intake.
Advise all patients to adequately hydrate with up to 3 L (twelve 8-oz glasses) of oralfluids (e.g. water, milk, or juice) per 24 hours on Days 1 through 8 of each 28-daytreatment cycle. In patients under 50 kg, up to 2 L (eight 8-oz glasses) per 24-hourperiod is recommended.
Consider low-dose aspirin on Days 1 through 8 of each 28-day treatment cycle.
This Healthcare Provider Instructions for Use has been approved by the U.S. Food and DrugAdministration.
LUMOXITI is a trademark of the AstraZeneca group of companies. © AstraZeneca 2018
Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850
Manufactured by: AstraZeneca AB, Södertälje, Sweden SE-151 85; U.S. License No. 2059
For more information, go to www.LUMOXITI.com or call 1-800-236-9933.
Issued: 9/2018
|
